JPMorgan Chase & Co. lifted its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 900.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 896,258 shares of the biopharmaceutical company's stock after acquiring an additional 806,672 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.47% of Arbutus Biopharma worth $2,931,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Arbutus Biopharma by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company's stock valued at $29,367,000 after purchasing an additional 62,282 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Arbutus Biopharma during the fourth quarter valued at $84,000. Teacher Retirement System of Texas lifted its stake in Arbutus Biopharma by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company's stock worth $138,000 after acquiring an additional 6,644 shares in the last quarter. Xponance Inc. acquired a new stake in Arbutus Biopharma during the 4th quarter worth about $34,000. Finally, Intech Investment Management LLC grew its stake in Arbutus Biopharma by 54.9% during the 4th quarter. Intech Investment Management LLC now owns 57,084 shares of the biopharmaceutical company's stock valued at $187,000 after acquiring an additional 20,232 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company's stock.
Arbutus Biopharma Stock Performance
Shares of NASDAQ ABUS opened at $3.19 on Wednesday. The business has a 50 day simple moving average of $3.28 and a 200 day simple moving average of $3.45. Arbutus Biopharma Co. has a 52 week low of $2.63 and a 52 week high of $4.73. The stock has a market cap of $610.82 million, a price-to-earnings ratio of -7.42 and a beta of 1.45.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. On average, analysts predict that Arbutus Biopharma Co. will post -0.39 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 28th. StockNews.com upgraded shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 29th. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Arbutus Biopharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.
View Our Latest Analysis on ABUS
About Arbutus Biopharma
(
Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Stories
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
